A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

Completed · Phase 3

Conditions studied: Diabetes, Diabetes Mellitus, Type 2

In brief

This trial was conducted in Africa, Asia, Europe, North and South America. The aim of the trial was to compare efficacy and safety of insulin degludec and insulin glargine in insulin naïve subjects with type 2 diabetes.

Key facts

Study ID

NCT01849289

Run by

Novo Nordisk A/S

People needed

833

Starts

2013-06-02

Expected to finish

2014-05-15

Last updated by the study team

2017-04-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months
• Insulin naïve subjects (Allowed are: previous short term insulin treatment up to 14 days; treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days)
• Current treatment: metformin monotherapy or metformin in any combination with an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitor, alfa-glucosidase-inhibitors (acarbose) with unchanged dosing for at least 3 months prior to randomisation (Visit 2) with the minimum doses stated: metformin: alone or in combination (including fixed combination) 1500 mg daily, or maximum tolerated dose (at least 1000 mg daily), insulin secretagogue (sulfonylurea or glinide): minimum half of the daily maximal dose according to local labelling, DPP-IV inhibitor: minimum 100 mg daily or according to local labelling, alfa-glucosidase-inhibitors (acarbose): minimum half of the daily maximal dose or maximum tolerated dose
• HbA1c (glycosylated haemoglobin) 7.0-10.0% (both inclusive) by central laboratory analysis
• BMI (Body Mass Index) below or equal to 40.0 kg/m\^2

You may not qualify if…

• Treatment with TZDs (thiazoledinedione), or GLP-1 (glucagon-like peptide 1) receptor agonists within the last 3 months prior to Visit 1 (screening)
• Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as systemic corticosteroids, beta-blockers, MAO (monoamine oxidase) inhibitors
• Cardiovascular disease within the last 6 months prior to Visit 1 (screening) defined as stroke; decompensated heart failure NYHA (New York Heart Association) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
• Any clinically significant disease or disorder, except for conditions associated with type 2 diabetes mellitus, which in the Investigator's opinion could interfere with the results of the trial
• Previous participation in this trial. Participation is defined as randomised. Re-screening of screening failures is allowed only once within the limits of the recruitment period
• Known or suspected hypersensitivity to trial product(s) or related products

Where it is running

• Novo Nordisk Investigational Site — Lomita, California, United States
• Novo Nordisk Investigational Site — Los Angeles, California, United States
• Novo Nordisk Investigational Site — Golden, Colorado, United States
• Novo Nordisk Investigational Site — Clearwater, Florida, United States
• Novo Nordisk Investigational Site — Chicago, Illinois, United States
• Novo Nordisk Investigational Site — Crestview Hills, Kentucky, United States
• Novo Nordisk Investigational Site — Metairie, Louisiana, United States
• Novo Nordisk Investigational Site — Troy, Michigan, United States
• Novo Nordisk Investigational Site — Chesterfield, Missouri, United States
• Novo Nordisk Investigational Site — Nashua, New Hampshire, United States
• Novo Nordisk Investigational Site — Toms River, New Jersey, United States
• Novo Nordisk Investigational Site — Smithtown, New York, United States
• Novo Nordisk Investigational Site — Simpsonville, South Carolina, United States
• Novo Nordisk Investigational Site — Jackson, Tennessee, United States
• Novo Nordisk Investigational Site — Dallas, Texas, United States
• Novo Nordisk Investigational Site — Newport News, Virginia, United States
• Novo Nordisk Investigational Site — Kenosha, Wisconsin, United States
• Novo Nordisk Investigational Site — São Paulo, São Paulo, Brazil
• Novo Nordisk Investigational Site — Porto Alegre, Brazil
• Novo Nordisk Investigational Site — São Paulo, Brazil
• Novo Nordisk Investigational Site — Calgary, Alberta, Canada
• Novo Nordisk Investigational Site — Burnaby, British Columbia, Canada
• Novo Nordisk Investigational Site — Surrey, British Columbia, Canada
• Novo Nordisk Investigational Site — Victoria, British Columbia, Canada
• Novo Nordisk Investigational Site — Anaheim, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.